Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging Valuation Landscape
· gurufocus.com
On September 23, 2026, Gossamer Bio Inc (NASDAQ: GOSS) announced the filing of a New Drug Application (NDA) with the FDA for seralutinib, its investigational tr
On September 23, 2026, Gossamer Bio Inc (NASDAQ: GOSS) announced the filing of a New Drug Application (NDA) with the FDA for seralutinib, its investigational tr...